Annonce

Log ud Log ind
Log ud Log ind

Novo Nordisk A/S – share repurchase programme

Henrik

mandag 25. november 2024 kl. 16:16

https://ml-eu.globenewswire.com/Resource/Download/18c2fb08-e2c1-4a52-90dd-5c0f18213eb6

Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Rules”). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.

Since the announcement 18 November 2024, the following transactions have been made:

 Number of
B sharesAverage
purchase priceTransaction
value, DKKAccumulated, last announcement431,987 322,447,00718 November 202480,000707.7556,619,91419 November 202480,000708.8956,711,04620 November 202480,000732.7458,619,35621 November 202480,000727.2758,181,80422 November 202480,000738.0759,045,300Accumulated under the programme831,987 611,624,426

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 22,179,644 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 22 November 2024, Novo Nordisk has since 6 February 2024 repurchased a total 21,035,086 B shares at an average share price of DKK 830.77 per B share equal to a transaction value of DKK 17,475,418,304.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs,

[postviewcount]

Relaterede nyheder

Jobannoncer

Udløber snart
Finance Controller – få sparringspartnere fra hele Europa (fuldtid)
Region Syddanmark

Log ind

Har du ikke allerede en bruger? Opret dig her.

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank